1570 related articles for article (PubMed ID: 20217518)
61. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO
Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076
[TBL] [Abstract][Full Text] [Related]
62. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.
Roep BO
Diabetologia; 2003 Mar; 46(3):305-21. PubMed ID: 12687328
[TBL] [Abstract][Full Text] [Related]
63. Role of immune system in type 1 diabetes mellitus pathogenesis.
Szablewski L
Int Immunopharmacol; 2014 Sep; 22(1):182-91. PubMed ID: 24993340
[TBL] [Abstract][Full Text] [Related]
64. Immune interventions to preserve β cell function in type 1 diabetes.
Ehlers MR
J Investig Med; 2016 Jan; 64(1):7-13. PubMed ID: 26225763
[TBL] [Abstract][Full Text] [Related]
65. Proinsulin: a unique autoantigen triggering autoimmune diabetes.
You S; Chatenoud L
J Clin Invest; 2006 Dec; 116(12):3108-10. PubMed ID: 17143326
[TBL] [Abstract][Full Text] [Related]
66. Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes.
Creusot RJ; Battaglia M; Roncarolo MG; Fathman CG
Stem Cells; 2016 Apr; 34(4):809-19. PubMed ID: 26840009
[TBL] [Abstract][Full Text] [Related]
67. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse.
Gallichan WS; Balasa B; Davies JD; Sarvetnick N
J Immunol; 1999 Aug; 163(3):1696-703. PubMed ID: 10415077
[TBL] [Abstract][Full Text] [Related]
68. Is facilitating pancreatic beta cell regeneration a valid option for clinical therapy?
Trucco M
Cell Transplant; 2006; 15 Suppl 1():S75-84. PubMed ID: 16826799
[TBL] [Abstract][Full Text] [Related]
69. Facilitating physiologic self-regeneration: a step beyond islet cell replacement.
Rood PP; Bottino R; Balamurugan AN; Fan Y; Cooper DK; Trucco M
Pharm Res; 2006 Feb; 23(2):227-42. PubMed ID: 16323065
[TBL] [Abstract][Full Text] [Related]
70. Peptide Immunotherapy for Type 1 Diabetes-Clinical Advances.
Smith EL; Peakman M
Front Immunol; 2018; 9():392. PubMed ID: 29541078
[TBL] [Abstract][Full Text] [Related]
71. How to make insulin-producing pancreatic β cells for diabetes treatment.
Lu J; Xia Q; Zhou Q
Sci China Life Sci; 2017 Mar; 60(3):239-248. PubMed ID: 27796637
[TBL] [Abstract][Full Text] [Related]
72. Life and death of β cells in Type 1 diabetes: A comprehensive review.
Wilcox NS; Rui J; Hebrok M; Herold KC
J Autoimmun; 2016 Jul; 71():51-8. PubMed ID: 27017348
[TBL] [Abstract][Full Text] [Related]
73. Gene therapy in type 1 diabetes.
Bagley J; Paez-Cortez J; Tian C; Iacomini J
Crit Rev Immunol; 2008; 28(4):301-24. PubMed ID: 19166382
[TBL] [Abstract][Full Text] [Related]
74. Relapsing/remitting type 1 diabetes.
van Megen KM; Spindler MP; Keij FM; Bosch I; Sprangers F; van Royen-Kerkhof A; Nikolic T; Roep BO
Diabetologia; 2017 Nov; 60(11):2252-2255. PubMed ID: 28835984
[TBL] [Abstract][Full Text] [Related]
75. Accessory cells for β-cell transplantation.
Staels W; De Groef S; Heremans Y; Coppens V; Van Gassen N; Leuckx G; Van de Casteele M; Van Riet I; Luttun A; Heimberg H; De Leu N
Diabetes Obes Metab; 2016 Feb; 18(2):115-24. PubMed ID: 26289770
[TBL] [Abstract][Full Text] [Related]
76. Harnessing the immunomodulatory and tissue repair properties of mesenchymal stem cells to restore β cell function.
Davis NE; Hamilton D; Fontaine MJ
Curr Diab Rep; 2012 Oct; 12(5):612-22. PubMed ID: 22869154
[TBL] [Abstract][Full Text] [Related]
77. Primary Human and Rat β-Cells Release the Intracellular Autoantigens GAD65, IA-2, and Proinsulin in Exosomes Together With Cytokine-Induced Enhancers of Immunity.
Cianciaruso C; Phelps EA; Pasquier M; Hamelin R; Demurtas D; Alibashe Ahmed M; Piemonti L; Hirosue S; Swartz MA; De Palma M; Hubbell JA; Baekkeskov S
Diabetes; 2017 Feb; 66(2):460-473. PubMed ID: 27872147
[TBL] [Abstract][Full Text] [Related]
78. Regenerative medicine for diabetes: differentiation of human pluripotent stem cells into functional β-cells in vitro and their proposed journey to clinical translation.
Bose B; Katikireddy KR; Shenoy PS
Vitam Horm; 2014; 95():223-48. PubMed ID: 24559920
[TBL] [Abstract][Full Text] [Related]
79. Induction of islet autoimmunity to defective ribosomal product of the insulin gene as neoantigen after anti-cancer immunotherapy leading to autoimmune diabetes.
van Tienhoven R; Jansen DTSL; Park M; Williams JC; Larkin J; Quezada SA; Roep BO
Front Immunol; 2024; 15():1384406. PubMed ID: 38596681
[TBL] [Abstract][Full Text] [Related]
80. New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement.
Couri CEB; Malmegrim KCR; Oliveira MC
Front Immunol; 2018; 9():1086. PubMed ID: 29868031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
